Compounders Research Compare

FibroBiologics, Inc. Common Stock(FBLG)

Biotechnology · Houston, TX

$1.18-0.06 (-4.84%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About FibroBiologics, Inc. Common Stock

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Houston, TX

15 employees

www.fibrobiologics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Peter O'Heeron

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T12:46:37.513Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:46:37.513Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,473,247
Total debt · period ending 2026-06-30: 1,462,000
Cash · period ending 2026-06-30: 3,515,000
TTM operating EBITDA · period ending 2026-06-30: -15,866,000

FMP input reference: f130e36c5816a2cced4d00ccb7d778b7baaa6bfdcaf5b95b3974dc9f748ee68d

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

FBLG EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

FBLG Competitors' EV/EBITDA Ratio

FibroBiologics, Inc. Common Stock

Current

Market Cap

$2.47M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Creative Medical Technology Holdings, Inc.

Market Cap

$2.37M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GeoVax Labs, Inc.

Market Cap

$2.36M

EV/EBITDA Ratio

N/A

TTM Avg

10388992794.84x

3Y Avg

12435877641.77x

5Y Avg

12435877641.77x

bioAffinity Technologies, Inc.

Market Cap

$2.59M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Autonomix Medical, Inc.

Market Cap

$1.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioRestorative Therapies, Inc.

Market Cap

$3.09M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adagio Medical Holdings, Inc.

Market Cap

$3.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cadrenal Therapeutics, Inc. Common Stock

Market Cap

$3.37M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curis, Inc.

Market Cap

$1.54M

EV/EBITDA Ratio

N/A

TTM Avg

341.73x

3Y Avg

341.73x

5Y Avg

341.73x

Aethlon Medical, Inc.

Market Cap

$3.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
FibroBiologics, Inc. Common Stock (FBLG)	$2.47M	N/A	N/A	N/A	N/A
Creative Medical Technology Holdings, Inc. (CELZ)vs ›	$2.37M	N/A	N/A	N/A	N/A
GeoVax Labs, Inc. (GOVX)vs ›	$2.36M	N/A	10388992794.84x	12435877641.77x	12435877641.77x
bioAffinity Technologies, Inc. (BIAF)vs ›	$2.59M	N/A	N/A	N/A	N/A
Autonomix Medical, Inc. (AMIX)vs ›	$1.92M	N/A	N/A	N/A	N/A
BioRestorative Therapies, Inc. (BRTX)vs ›	$3.09M	N/A	N/A	N/A	N/A
Adagio Medical Holdings, Inc. (ADGM)vs ›	$3.13M	N/A	N/A	N/A	N/A
Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs ›	$3.37M	N/A	N/A	N/A	N/A
Curis, Inc. (CRIS)vs ›	$1.54M	N/A	341.73x	341.73x	341.73x
Aethlon Medical, Inc. (AEMD)vs ›	$3.44M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics